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ABSTRACT
Cyclosporine-based immunosuppression is common after allogeneic hematopoietic stem cell transplan-
tation (HSCT). Elevated cyclosporine concentrations are associated with significant toxicity and often
result in the temporary cessation or discontinuation of cyclosporine. Low blood concentrations also result
in significant immunologic risks, primarily graft-versus-host disease and loss of stem cell graft. The
pharmacokinetics of cyclosporine are highly complex, and maintaining therapeutic and safe cyclosporine
concentrations are challenging. Several clinical factors are known to independently influence in vivo
cyclosporine pharmacokinetic behavior. However, in the critically ill patient, several of these clinical
factors are generally present simultaneously. Unfortunately, there are no studies that have evaluated the
combined effects of these clinical factors on cyclosporine disposition in HSCT. The objective of our study
is to determine the population pharmacokinetic parameters of intravenous and oral cyclosporine, evaluate
the effects of clinical covariates on cyclosporine pharmacokinetics, and develop a model that estimates
clearance (Cl) and dose requirements for an individual HSCT patient with these clinical covariates. The
authors analyzed 740 cyclosporine steady-state whole blood concentrations in 129 adult patients obtained
between day 0 and discharge or 60 days posttransplant, whichever came first. Patients received intravenous
cyclosporine at 2.5 mg/kg every 12 hours if body weight was greater than 50 kg, 2.5 mg/kg every 8 hours
if less than 50 kg, or 5 to 7.5 mg/kg/d given as a continuous infusion, beginning on day-3. Patients were
converted to oral therapy as tolerated. The influence of clinical covariates on the Cl of cyclosporine was
tested with a nonlinear mixed effects model (NONMEM). The tested clinical covariates were age, height,
body weight on admission, body surface area, sex, type of hematologic malignancy, transplant type,
preparative regimen, baseline serum creatinine, T-cell depletion of graft, number of methotrexate doses,
day of onset, and maximum grade of acute graft-versus-host disease. The route and frequency of
cyclosporine administration, day posttransplant, total bilirubin level, serum creatinine level, actual body
weight, presence of concurrent CYP450 enzyme inhibitors and inducers, or nephrotoxins on the day of the
cyclosporine blood measurement were also evaluated. Cyclosporine Cl significantly decreased each week
posttransplant. The authors found no significant effect of any of the other tested covariates including total
bilirubin on Cl. The final regression model for the estimation of Cl is: Cl (L/hr)  ([body weight in kg 
70] * 0.183  22.3) * (day posttransplant factor). The corresponding day posttransplant factor estimates are
1.46, 1.32, 1.20, and 1.0 during days 0 to 7, 8 to 14, 15 to 21 and greater than 21 posttransplant,
respectively. The interindividual variability in Cl was 27.7%. The dose of intravenous or oral cyclosporine
can be calculated using the estimated Cl. Understanding cyclosporine pharmacokinetics and the clinical
events that lead to alterations in Cl and exposure is critical in optimizing immunosuppressive therapy. The
authors found that cyclosporine Cl significantly decreased posttransplant until day 21. A pharmacokinetics
model was developed that incorporates the day posttransplant to predict cyclosporine Cl. Cyclosporine
dose requirements in an individual HSCT patient to achieve the desired therapeutic blood target can be
estimated using this model.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplanta-
tion (HSCT) is increasingly used for the treatment of
many malignant and nonmalignant diseases. Unfortu-
nately, posttransplant toxicity and immunologic com-
plications, such as poor engraftment and graft-versus-
host disease (GVHD), are barriers to successful
transplantation. The optimal immunosuppressive reg-
imen to enhance engraftment, limit GVHD while
providing graft versus tumor effects, and avoid toxic-
ity, is controversial. Because the goal of immunosup-
pression varies with the type and indication for trans-
plantation, the intensity of immunosuppression must
be modiﬁed easily for an individual patient. However,
scientiﬁc methods for altering immunosuppressive in-
tensity are not available. In practice, cyclosporine
doses are reduced or increased arbitrarily, thus often
missing the therapeutic target.
Cyclosporine is the most commonly used prophy-
lactic immunosuppressive agent in HSCT, primarily
in combination with methotrexate.[1, 2] Several stud-
ies have evaluated the relationships between cyclo-
sporine plasma or blood concentrations and GVHD
or toxicity. Most have concluded that low cyclospor-
ine concentrations increase the risk of GVHD and
that elevated concentrations are associated closely
with toxicity.[3-8] Therefore, most centers have es-
tablished targets for trough concentrations between
150 and 400 ng/mL.
Cyclosporine is pharmacologically and pharma-
cokinetically complex, and, as a result, drug expo-
sure is difﬁcult to predict. It is extensively metabo-
lized in the gut and liver by cytochrome P4503A
enzymes to numerous active and inactive metabo-
lites.[9] It has high intra- and interpatient pharma-
cokinetic variability [10]. It has low and highly vari-
able oral absorption, which is dependent on dose
formulation, disease state, and presence of food and
bile in the gut [11, 12]. Cyclosporine is also a potent
inhibitor of cytochrome P4503A enzymes; it is
highly protein bound and has a narrow therapeutic
range [13-15]. Hence, therapeutic monitoring of
cyclosporine blood concentrations and subsequent
adjustment of doses are mandatory.
Despite years of extensive clinical experience with
cyclosporine and the development of clinical algo-
rithms for dose adjustments, prompt achievement and
maintenance of the cyclosporine therapeutic target is
still difﬁcult. It is common for patients to require
multiple dose alternations in the early posttransplant
period. Failure or delay in achieving the blood con-
centration target can result in renal dysfunction, hy-
pertension, hyperglycemia, and central nervous sys-
tem or infectious toxicities, as well as serious
immunologic complications such as GVHD or poor
engraftment. Hence, a model that predicts cyclospor-
ine disposition and dose requirements to achieve the
desired therapeutic target in an individual patient
would be highly useful.
Few cyclosporine pharmacokinetic studies have
been performed in HSCT, and most have evaluated
small numbers of subjects. Studies have evaluated the
effect of a single clinical factor (eg, bilirubin) on cy-
closporine disposition, but none have evaluated the
combined effect of clinical factors. Therefore, the
objective of our study is to determine the population
pharmacokinetic parameters of intravenous and oral
cyclosporine in a large number of patients, evaluate
the effect of clinical covariates on cyclosporine clear-
ance (Cl), and develop a model that would estimate
individual dose requirements.
MATERIALS AND METHODS
Study Population
Data were obtained retrospectively from the med-
ical records, medication administration records, and
the Bone Marrow Transplant Program database from
a random selection of 152 adult patients who had
undergone related or unrelated allogeneic stem cell
transplantation between the years of 1992 and 2001 at
the University of Minnesota. All patients signed in-
formed consent before transplantation. Complete data
were available in 129 (85%) patients and were used in
this analysis.
GVHD Prophylaxis
All patients received intravenous cyclosporine be-
ginning on day 3 as an intermittent infusion over 2
hours of 2.5 mg/kg every 12 hours if body weight was
greater than 50 kg or 2.5 mg/kg every 8 hours if less
than 50 kg, or 5 to 7.5 mg/kg/d given as a continuous
infusion. Oral cyclosporine (Neoral or Sandimmune,
Novartis Pharmaceuticals, East Hanover, NJ) was
substituted at 2 or 3 times the intravenous dose, when
tolerated. In patients without GVHD, full-dose cyclo-
sporine therapy was continued, at a minimum, until
day 60. Methotrexate (10 to 15 mg/m2) was given in
conjunction with cyclosporine on days 1, 3, 6, and 11
to the majority of patients (Table 1).
Cyclosporine Steady-State Blood Concentrations
Cyclosporine whole blood concentrations were
measured beginning 4 days after initiation of therapy
and then approximately twice a week thereafter during
the hospital stay as part of routine patient care. Pa-
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tients with cyclosporine toxicity or cyclosporine dose
changes received more frequent measurements.
Trough cyclosporine concentrations were measured
during intermittent intravenous and oral therapy.
Morning cyclosporine blood concentration measure-
ments were obtained for patients on continuous intra-
venous infusion. Only concentrations obtained at
steady state were analyzed. Steady state was deﬁned as
at least 60 hours (4 estimated t1⁄2  8 to 15 hours) of
the same dose and route of cyclosporine administra-
tion [16-18]. Cyclosporine concentrations obtained up
to hospital discharge or 60 days posttransplant, which-
ever came ﬁrst, were included in this analysis. Cyclo-
sporine was held, or the dose was adjusted based on
blood concentrations, serum creatinine level, total bil-
irubin level, hypertension, hyperglycemia, and neuro-
toxicity. The targeted cyclosporine whole blood con-
centration was 200 to 400 ng/mL. Whole blood
cyclosporine concentrations were measured by high-
pressure liquid chromatography (HPLC) using mod-
iﬁcations of previously published assays [19-21]. The
HPLC system consisted of a Thermo Separation sys-
tem with a model P1000 pump, an AS3000 autosam-
pler, and a Hewlett Packard 3365 ChemStation
(Hewlett Packard, Palo Alto, CA). Detection was per-
formed by a Thermo Separation model UV1000 vari-
able wavelength detector with wavelength set at 214
nm. Separation was performed using a Superlcosil
LC-18 column, 4.6  33 mm, particle size 3 m
(Sigma-Aldrich, USA) and protected by a Supelco
LC-8, 5-m guard column. The mobile phase con-
sisted of acetonitrile/methanol/water (44:20:36 vol/
vol/vol). Flow rate was 2 mL/min. In brief, 2 mL of
lysing solution (30% acetonitrile in water) was added
to 1 mL whole blood patient sample and centrifuged
for 5 minutes at 1200g. Solid-phase extraction C-18
columns were conditioned using ethyl acetate, aceto-
nitrile and 50% acetonitrile in water. The lysate mix-
ture was applied to the extraction columns. After 2
washes with 50% acetonitrile in water, the samples
were eluted with ethyl acetate. The samples were
evaporated to dryness; reconstituted in buffer mixture
containing ammonium sulfate, acetonitrile, and meth-
anol; and 150 L was injected into HPLC. Coefﬁcient
of variation (CV%) of the assay at 25 ng/mL was
6.4%.
Data Collection
Baseline patient characteristics collected were age,
recipient sex, disease, transplant type, preparative reg-
imen, total body weight, height, body surface area,
serum creatinine (SCr), T-cell depletion of graft,
GVHD prophylaxis, and number of methotrexate
doses given. Additional data were recorded with each
cyclosporine trough concentration: cyclosporine dose;
route of administration; brand of oral cyclosporine
(Sandimmune or Neoral); day posttransplant; cur-
rent total body weight; SCr; total bilirubin level; ala-
nine aminotransferase (ALT); alkaline phosphatase;
presence of concurrent cytochrome P450 inhibitors
(itraconazole, ﬂuconazole, diltiazem, amlodipine), in-
ducers (prednisone, methylprednisolone), or nephro-
toxins (amphotericin B, aminoglycoside, foscarnet);
presence of venooclusive disease (VOD); and maxi-
mum grade and date of onset of acute GVHD.
Diagnosis of GVHD and VOD
The day of onset and the most severe grade of
acute GVHD for each patient were obtained during
the study period. GVHD was diagnosed and graded
according to standard clinical and pathologic charac-
teristics [22]. Skin, gut, and liver biopsy specimens
were obtained whenever possible. GVHD was graded
by standard clinical criteria [23, 24], GVHD consen-
sus conference criteria [25], and the International
Bone Marrow Transplant Registry severity index [26].
All GVHD diagnoses were conﬁrmed by a senior
attending physician. VOD was diagnosed clinically in
the presence of hyperbilirubinemnia, ascites, and hep-
atomegaly.
Population Pharmacokinetic Modeling of
Clearance and Bioavailability
A nonlinear mixed effects model (NONMEM),
version V, level 1.0 [27] with double precision analysis
was used for this analysis. Cyclosporine blood concen-
trations obtained at steady state during intravenous
and oral administration were analyzed to estimate the
Table 1. Patient Characteristics
No. of patients 129
Age in years, median (range) 40 (19–60)
Weight on admission (kg) 77 (47–156)
Sex
Male 69 (53%)
Female 60 (47%)
GVHD prophylaxis
Cyclosporine/methotrexate 113 (88%)
Other (CSA, CSA/ATG, CSA/ATG/MP,
CSA/MP, CSA/MTX/IL-IRA) 16 (12%)
Transplant type
Related donor 88 (68%)
Unrelated donor 41 (32%)
Conditioning regimens
Cyclophosphamide, total body irradiation
(Cy TBI) 95 (74%)
Busulfan, cyclophosphamide (Bu Cy) 10 (8%)
Other 24 (18%)
T-cell depletion 11 (9%)
No. MTX doses received
4 69 (53%)
3 30 (23%)
2 13 (10%)
1 1 (1%)
TBI indicates total body irradiation; MTX, methotrexate; ATG,
antilymphocyte immunoglobulin; MP, methylprednisolone; IL-
1RA, interleukin-1 receptor antagonist.
P. A. Jacobson et al.
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population pharmacokinetic parameters of interest,
Cl, oral bioavailability [F], and their variabilities.
In a population pharmacokinetic analysis, all con-
centrations from all subjects are analyzed simulta-
neously to estimate the relevant parameters. The re-
gression equation relating average steady-state
concentration (Css), Cl, and dosing rate (Ro) is
straightforward in the case of continuous intravenous
infusions and the following standard pharmacokinetic
relationship was used.
Css  Ro/Cl (1)
where Ro (mg/h) was the infusion rate of cyclosporine
and Cl (L/h) was the Cl. For intermittent dosing (eg,
every 8 or every 12 hr) at steady state, the Css over a
steady-state dosing interval was modeled as
Css  F  D/(Cl  ) (2)
where D is the dose in milligrams, tau () is the dosing
interval in hours, and F is the oral bioavailability.
However, in therapeutic drug monitoring settings, a
steady-state trough concentration (Cmin), not Css, is
most commonly obtained. Although the equation for
Cmin is available, it requires the additional pharmaco-
kinetic parameters of volume of distribution and ab-
sorption rate constant (for oral dosing) to characterize
it. Multiple concentrations must be obtained in the
ﬁrst few hours after dosing to estimate these parame-
ters. In our situation, only trough concentrations were
available, and it was not possible to obtain these esti-
mates. One option would have been to ﬁx these pa-
rameters to literature values and estimate Cl and F.
However, the equation for Cmin in intermittent dosing
is complicated to work with in the clinical setting, and,
therefore, a simpler approach was used. We chose to
model our dependent variable, Cmin, with an equation
quite similar to Css.
Cmin  FF  D/(Cl  ) (3)
where FF is a parameter that compensates for the
difference between Css and Cmin and also includes
bioavailability for oral dosing. In intermittent intrave-
nous dosing, bioavailability is 100%, and FF is theo-
retically the ratio Cmin to Css. This approach has the
advantage of allowing the same population Cl term to
be used when predicting concentrations that result
from continuous intravenous infusions, intermittent
intravenous doses, and oral doses. It should be noted
that when the half-life of a drug is long relative to the
dosing interval, the difference between a Cmin and Css
is small.
Interindividual variabilities in Cl and F were mod-
eled as log-normal distributions. Residual variability
was characterized by a combined proportional and
additive model that allowed the residual error to in-
crease with the value of the predicted concentration
but not in a strictly proportional way.
Development of the Regression Model to
Determine Influence of Covariates on Clearance
A forward inclusion and backward elimination ap-
proach was used to build a regression model for Cl.
Nineteen covariates were entered into a regression
model as continuous or dichotomous variables.
Height, total body weight, and body surface area are
examples of continuous variables evaluated. Continu-
ous variables were modeled linearly using slope and
intercept parameters after centering the covariate
about its standard value. For example, the inﬂuence of
subject weight (WT, in kg) on Cl was modeled in the
following way.
Cl  slope  (WT  70)  intercept (4)
Other covariates such as sex are true dichotomous
variables and enter the regression equation as a mul-
tiplier associated with the covariate. This notion can
be extended easily to include distinct multipliers for
covariates with more than 2 groups, ie, type of drug
administration (continuous infusion, intermittent in-
fusion, or oral dosing). Some continuous covariates
may not follow a strictly linear relationship; rather
than proposing a complicated nonlinear function with
multiple parameters, it can be useful to divide the
continuous variable into groups and model each group
as having its own multiplier. Serum creatinine (Scr 
1, 1 to 1.9, 2 mg/dL) is such an example. The
relationships between Cl and age (30 v 	30, 40
v 	 40, 50 v 	50 years), recipient sex (male v
female), transplant type (related v unrelated), T cell
depletion by elutriation (yes v no), preparative regi-
men (Cy/TBI v Bu/Cy v other), GVHD prophylaxis
regimen (CSA/MTX v other), number of adminis-
tered MTX doses (0 to 4), days posttransplant (7, 8
to 14, 15 to 21, 22 to 28, 29 to 60), cyclosporine
dosing interval (every 8 hr, every 12 hr, continuous
infusion), route of administration (oral, continuous
infusion, intermittent infusion), SCr (1, 1 to 1.9, 2
mg/dL), total bilirubin (1, 1 to 1.9, 2 to 2.9, 3 to 3.9,
4 to 9.9, 10 mg/dL), presence of concurrent
CYP450 inhibitor(s), inducer(s), or nephrotoxin(s)
(yes v no), and grade of GVHD (0 to 4) were inves-
tigated. The inﬂuence of covariates on bioavailability
was not evaluated because of the small number of
concentrations obtained during oral administration.
During forward inclusion, a change in objective
function of greater than 6.6 in testing a single covari-
ate was statistically signiﬁcant (
2, df 1; P .01). All
covariates producing a signiﬁcant reduction in the
objective function were used to construct the full re-
gression model. During backward elimination, each
covariate was eliminated individually from the full
regression model to conﬁrm its signiﬁcance. If the
objective function increased by more than 6.6, re-
moval of the covariate resulted in a model that was
signiﬁcantly inferior (
2, df  1; P  .01), and it was
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concluded that the covariate was contributing unique
information. A ﬁnal model was constructed that kept
only those covariates that maintained signiﬁcance dur-
ing backward elimination.
RESULTS
Patient characteristics are summarized in Table 1.
We obtained 1070 cyclosporine whole blood concen-
trations in 129 adult HSCT patients. Cyclosporine
concentrations that were not obtained at steady state
(n  256) or obtained while cyclosporine was tempo-
rarily held (n  74) were excluded from the analysis.
The ﬁnal data set consisted of 740 cyclosporine blood
concentrations: 663 during intermittent intravenous
infusion (every 8 hours, n50; every 12 hours,
n613), 36 during continuous intravenous infusion,
and 41 during oral therapy (Sandimmune, n  8;
Neoral, n  33). A median of 5 cyclosporine concen-
trations (range, 1 to 15) were obtained per patient.
Fifty-nine cyclosporine concentrations were evaluated
in patients with SCr  2 mg/dL. There were 226 and
63 concentrations that were obtained when bilirubin
level was 2 to 9.9 and 10 mg/dL, respectively. No
patients had a conﬁrmed diagnosis of VOD. Acute
grade II and III/IV GVHD were present when 35 and
21 of the cyclosporine concentrations were obtained,
respectively. Cyclosporine concentrations were ob-
tained for this analysis for a median of 11 days (range,
0 to 59) posttransplant. Two hundred ninety-seven
concentrations were obtained between days 0 and 7,
143 between days 8 and 14, 119 between days 15 and
21, and 181 between days 22 and 60 posttransplant.
The number of cyclosporine concentrations obtained
while receiving a CYP450 inhibitor or inducer was
586 (79%) and 142 (19%), respectively. One hundred
seven concentrations were obtained when the subject
was receiving a CYP450 inducer and inhibitor. A
nephrotoxin(s) was concomitantly prescribed when
145 of the cyclosporine concentrations were obtained.
Estimate of Population Clearance
The pharmacokinetic population estimates for cy-
closporine Cl and FF’ are shown in Table 2. During
forward inclusion, subject weight, number of adminis-
tered methotrexate doses, SCr, and day posttransplant
were statistically signiﬁcant covariates, and sex was mar-
ginally signiﬁcant in predicting cyclosporine Cl. We
found no effect of the other tested clinical covariates on
cyclosporine Cl in forward inclusion. In particular, we
found no signiﬁcant effect of total bilirubin on cyclo-
sporine Cl, despite the presence of 289 cyclosporine
concentrations in patients with hyperbilirubinemia.
However, in backward elimination, only weight and day
posttransplant were retained in the model. Cyclosporine
Cl signiﬁcantly decreased during the ﬁrst 21 days post-
transplant. The ﬁnal regression model for the estimation
of Cl in an individual subject is:
Cl (L/hr) 
([Wt in kg 70]  0.183 22.3)  (DPT factor) (5)
The DPT factor is a multiplier that adjusts Cl for the
number of days post transplant. Cl declined for the
ﬁrst 3 weeks posttransplant. The DPT factor esti-
mates are 1.46, 1.32, 1.20, and 1.0 during days 0 to 7,
8 to 14, 15 to 21 and greater than 21 posttransplant,
respectively.
The variability of Cl in the population was 27.7%.
Data were insufﬁcient to estimate the intersubject
variability in FF. The residual variability expressed as
a coefﬁcient of variation (CV) decreased as the cyclo-
sporine concentrations increased. The estimated CVs
were 58% and 26% at predicted cyclosporine concen-
trations of 150 and 400 ng/mL, respectively.
DISCUSSION
The pharmacokinetics of cyclosporine are highly
complex, and several clinical factors independently
inﬂuence its in vivo behavior. However, in the criti-
Table 2. Cyclosporine Pharmacokinetic Parameters
Population
Pharmacokinetics
Estimate Standard Error
Clearance (L/h) in a 70-kg patient 22.3 2.14
Clearance change for each 1-kg increase in body weight 0.183* 0.0424
Continuous infusion FF 1.0
Intermittent infusion FF 0.452 0.0396
Oral dosing FF 0.270 0.0439
Day posttransplant (DPT) modifying factor of Cl
Days 0–7 1.46* 0.0953
Days 8–14 1.32* 0.0770
Days 15–21 1.20* 0.0847
Days 22–60 1.0
Interindividual variability CV
Clearance 27.7% 0.0121
*Clearance is adjusted by these values, as applicable.
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cally ill patient, several of these clinical factors are
generally present simultaneously. Unfortunately, no
studies have evaluated the combined effects of these
clinical factors on cyclosporine disposition in HSCT.
Because of the difﬁculty encountered in achieving and
maintaining the cyclosporine therapeutic target, we
hypothesized that several clinical factors simulta-
neously inﬂuenced its disposition and that we could
build a model to predict its disposition. Therefore, we
evaluated our data with population pharmacokinetic
analysis, estimated cyclosporine Cl, and studied the
effect of clinical factors on Cl. The cyclosporine pop-
ulation Cl estimate was 22.3 L/h and is similar to
previous estimates in HSCT (8.4 to 16.2 L/hr), which
also measured whole blood cyclosporine concentra-
tions by HPLC [28].
Also of interest is the estimate of the FF param-
eter that was modeled to represent the ratio Cmin to
Css for intermittent infusions. Based on the literature,
the standard patient would have a cyclosporine half-
life of 8 hours, a volume of distribution of 4 L/kg, and
an absorption rate constant of 1.5 h-1. If this standard
patient received 2.5 mg/kg every 12 hours adminis-
tered as a 1-hour infusion, the Cmin to Css ratio can be
calculated to be 0.55. NONMEM estimated this pa-
rameter to be 0.45. The close proximity of this esti-
mate to its expected value supports the ability of this
model to simultaneously estimate the population Cl
and accommodate for the discrepancy between mea-
sured Cmin and Css concentrations.
An estimate of oral bioavailability can also be ob-
tained from these parameters because the FF param-
eter after oral dosing is the product of bioavailability
and the Cmin to Css ratio. Using the one-compartment
equations for oral dosing at steady state, standard
pharmacokinetic parameters and standard dosing, the
Cmin to Css ratio is 0.60, or 10.8% larger than typical
value with intermittent intravenous infusions. One can
adjust the NONMEM estimate of the intravenous FF
by this amount and then assume that this approxi-
mates the oral Cmin to Css ratio without the bioavail-
ability factor. Bioavailability can then be solved for as
0.27/(0.45 * 1.108), which equates to 54%. This is
similar to bioavailability estimates of Neoral in HSCT
and consistent with clinical practice of converting in-
travenous to oral cyclosporine at a 1:2 ratio [29]. We
found that cyclosporine Cl is modiﬁed by body weight
and that Cl declined out to day 21 posttransplant. In a
previous study in HSCT, a decline of approximately
50% in cyclosporine Cl was observed in the ﬁrst 2
weeks posttransplant [28]. The mechanism for a de-
creasing Cl over time is unclear, but we postulate that
hepatic cytochrome P450 metabolism, enterohepatic
recycling, or bile formation/excretion may be reduced
owing to chemotherapy or transplant related toxicity.
We found no dramatic effect of total bilirubin on
cyclosporine Cl, despite the inclusion of 289 cyclo-
sporine concentrations obtained in patients with a
total bilirubin level of 2 mg/dL. An older pharma-
cokinetic study in HSCT measured cyclosporine Cl
after oral administration in patients with no, mild
(bilirubin 1.2 to 2 mg/dL) or moderate (bilirubin 	2
mg/dL) hepatic dysfunction [30]. They observed that
patients with moderate hepatic dysfunction had a
lower mean cyclosporine oral Cl (29.60  7.10 mL/
min/kg) than the other groups (50.2 to 52.4 mL/min/
kg). Similar reductions in Cl during hepatic impair-
ment have also been observed in renal transplantation
[31]. However, in the above-referenced studies, cyclo-
sporine concentrations were measured with a nonspe-
ciﬁc radioimmunoassay, which is well known to cross
react with cyclosporine metabolites. Cross-reactive as-
says overestimate cyclosporine concentrations partic-
ularly in the setting of hepatic dysfunction where
metabolites readily accumulate [30, 32, 33]. As a re-
sult, Cl estimates are lower compared with those ob-
tained from concentrations measured by speciﬁc as-
says such as HPLC. Hence, it is not surprising that we
and others did not observe signiﬁcant changes in cy-
closporine Cl in patients with hyperbilirubinemia [18].
The effect of gut toxicity and acute GVHD on
cyclosporine pharmacokinetics is controversial. Cy-
closporine area under the curve (AUC) and the max-
imum observed concentration (Cmax) were reported
after 2 single oral doses of Neoral in adult (n  20)
and pediatric (n  5) patients who underwent alloge-
neic HSCT [34]. Subjects with gastrointestinal toxic-
ity had a higher Cmax and AUC than those without
toxicity, which was hypothesized to be caused by in-
creased capillary permeability or decreased gut cyto-
chrome P450 activity leading to increased absorption.
However, a previous study of oral cyclosporine in
HSCT found marked reductions in cyclosporine se-
rum concentrations in patients with gut dysfunction
caused by chemotherapy/radiation or acute GVHD
[35]. Low concentrations were presumed to be caused
by poor oral cyclosporine absorption. Because meth-
otrexate is a common part of our immunosuppressive
regimen, and it is well known to enhance chemother-
apy-induced toxicity, we evaluated its effects on cyclo-
sporine Cl. We did not detect any changes in cyclo-
sporine Cl directly attributable to the intensity of
methotrexate. However, this does not necessarily ex-
clude the effect of methotrexate on bioavailability be-
cause few patients were receiving oral cyclosporine at
the time of methotrexate administration and at the
height of their mucositis. We observed no effects of
acute GVHD on cyclosporine Cl; however, we only
evaluated pharmacokinetic data in hospitalized pa-
tients. Because the onset of acute GVHD may have
occurred after discharge, we cannot conclusively ex-
clude the potential effect of GVHD. It will be impor-
tant in the future studies to evaluate these effects in
the outpatient setting.
Age has been shown to signiﬁcantly inﬂuence cy-
closporine pharmacokinetics in HSCT. After oral ad-
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ministration of Neoral, children have a lower AUC
than adults (976  628 v 2742  1589 g hr/L,
respectively; P .02). Cmax and trough concentrations
were also lower [34]. After intravenous cyclosporine,
Cl is inversely related to age [36]. We did not ﬁnd an
effect of age on cyclosporine Cl in our study popula-
tion; however, all of our patients were adult subjects.
Cyclosporine pharmacokinetics are well known to be
inﬂuenced by induction or inhibition of the cytochrome
P450 enzyme system [18, 37-39]. We did not ﬁnd a
signiﬁcant effect of the presence of a cytochrome P450
inducer or inhibitor on cyclosporine Cl. However, in
79% of cases, a concomitant CYP450 inhibitor (usually
prophylactic ﬂuconazole or itraconazole) was present
and therefore there may have been too few individuals in
the no-inhibitor group to detect an effect.
Yee et al [36] reported that hematocrit signiﬁcantly
inﬂuenced cyclosporine pharmacokinetics. Cyclosporine
binds extensively to red blood cells. As hematocrit de-
creases in the early transplant period, cyclosporine Cl
increases presumably because of an increase in the frac-
tion of unbound drug in the blood. However, we were
unable to evaluate the effect of hematocrit on pharma-
cokinetic disposition. Because a hematocrit was infre-
quently measured on the same day as the cyclosporine
concentration and because of the high frequency of red
blood cell transfusions in the early posttransplant period,
we felt that using hematocrit values may have led to
erroneous covariate analysis. Therefore, we chose not to
evaluate the effect of hematocrit. Previous reports in
heart transplantation did not ﬁnd an inﬂuence of hemat-
ocrit on cyclosporine Cl [18].
In our institution, cyclosporine blood concentra-
tions are measured at least twice weekly in HSCT
recipients. Individuals with concentrations falling out-
side the therapeutic range (200 to 400 ng/mL) receive
cyclosporine dose adjustments. Elevated cyclosporine
concentrations are associated with toxicity and often
result in the temporary cessation or discontinuation of
cyclosporine. Low blood concentrations also result in
signiﬁcant risks; primarily GVHD and loss of stem
cell graft. Repeated cyclosporine blood concentration
measurements and dose adjustments are time and re-
source intensive for the clinician and difﬁcult for the
patient. Hence, a model that can predict cyclosporine
disposition and the clinical characteristics associated
with altered disposition would be highly useful in our
practice. Therefore, we have developed a clinical
model to predict cyclosporine Cl from which individ-
ual dose requirements can be estimated to achieve a
given cyclosporine blood concentration. However,
only day posttransplant was able to explain a signiﬁ-
cant portion of cyclosporine variability, and a substan-
tial amount of the variability still remained unex-
plained by the model. Therefore, yet-undeﬁned
pharmacogenetic factors may play a signiﬁcant role in
determining disposition.
The following example illustrates how the regression
model for Cl may be used in a clinical setting. The
equations have been algebraically rearranged to simplify
their use in determining an initial cyclosporine dose.
Consider a 75-kg adult, day 5 posttransplant,
with a desired cyclosporine concentration of 200
ng/mL (0.2 mg/L).
Total Daily Dose  Ctarget  Cl  1/FF  24
 Ctarget  {[(WT70)  0.183  22.3]
 DPT factor}  1/FF  24
where the total daily dose is in mg, Ctarget is the
desired target concentration at steady state, in milli-
grams per liter, WT is patient current weight in kilo-
grams, DPT factor is the day posttransplant factor and
varies according to the posttransplant day (days 0 to 7,
1.46; days 8 to 14, 1.32; days 15 to 21, 1.20; days 22 to
60, 1.00) and FF, which depends on the desired route
of administration (continuous intravenous infusion, 1;
intermittent intravenous infusion, 0.452; intermittent
oral dosing, 0.270).
If a continuous infusion is desired, the total daily
dose can be calculated as
0.2  75  70  0.183
 22.3  1.46  1/1  24
 162.7 mg/d, or 6.8 mg/hr
If an intermittent infusion is desired, the total daily
dose is
0.2  75  70  0.183
 22.3  1.46  1/0.452  24
 359.9 mg/d, or 180 mg q12 hr
If oral dosing is desired, the total daily dose is
0.2  75  70  0.183
 22.3  1.46  1/0.270  24
 603 mg/d, or 300 mg q12 hr
We found that day posttransplant signiﬁcantly inﬂu-
enced the Cl of cyclosporine, but signiﬁcant interpa-
tient variability remains unexplained. Other tested co-
variates including bilirubin level had little predictive
value in determining cyclosporine Cl. Therefore, it is
possible that factors such as cytochrome P450 3A5
genotypes and drug transporter proteins (eg, P-glyco-
protein) may be important and should be evaluated in
future studies. Understanding cyclosporine pharma-
cokinetics and the clinical events that lead to alter-
ations in Cl and immunosuppressive exposure in
HSCT is critical in improving clinical outcomes. De-
veloping clinical models that can predict immunosup-
pressive exposure is an important factor in reducing
toxicity, preventing and controlling GVHD, and pro-
moting engraftment.
P. A. Jacobson et al.
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